Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Alto Neuroscience (ANRO) EBITDA (2023 - 2026)

Alto Neuroscience has reported EBITDA over the past 4 years, most recently at -$27.1 million for Q1 2026.

  • Quarterly results put EBITDA at -$27.1 million for Q1 2026, down 73.12% from a year ago — trailing twelve months through Mar 2026 was -$77.8 million (down 11.34% YoY), and the annual figure for FY2025 was -$66.4 million, up 3.27%.
  • EBITDA reached -$27.1 million in Q1 2026 per ANRO's latest filing, down from -$17.1 million in the prior quarter.
  • Across five years, EBITDA topped out at -$7.2 million in Q1 2023 and bottomed at -$27.1 million in Q1 2026.
  • Median EBITDA over the past 4 years was -$15.7 million (2025), compared with a mean of -$15.4 million.
  • The largest annual shift saw EBITDA plummeted 101.0% in 2024 before it grew 20.84% in 2025.
  • Over 4 years, EBITDA stood at -$11.8 million in 2023, then crashed by 44.47% to -$17.0 million in 2024, then dropped by 0.34% to -$17.1 million in 2025, then plummeted by 59.12% to -$27.1 million in 2026.
  • Business Quant data shows EBITDA for ANRO at -$27.1 million in Q1 2026, -$17.1 million in Q4 2025, and -$15.0 million in Q3 2025.